Puma Pharma (@PumaPharma) / Twitter
PHARMA JONPI .: 08/24/14
PUMA BIOTECHNOLOGY, INC. : Precios y cotizaciones Acción | PBYI | US74587V1070 | MarketScreener
Exhibitor Puma Biotechnology 11-6 - Scripps CME Connection
Resumen: Puma Biotechnology y Pierre Fabre firman acuerdo de licencia exclusiva para desarrollar y comercializar NERLYNX® (neratinib) en Europa | Business Wire
Compra Acciones de Puma Biotechnology Inc y Comprueba ($PBYI) su Precio de Mercado en eToro.
Puma Biotechnology
Puma Biotechnology
Puma Men – PHARMA
Puma Biotechnology
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
Puma – PHARMA
Puma Biotechnology: Too Little, Too Late, Too Much Of A Bad Side Effect (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
Puma Biotechnology
Does Puma's quick Nerlynx launch play into its buyout prospects? | Fierce Pharma
Puma Wins 5-Year Extension of Patent on Main Breast Cancer Treatment Drug Nerlynx - Los Angeles Business Journal
Ex-Puma exec charged with insider trading, hit with criminal charges | Fierce Biotech
La EMA recomienda no aprobar el fármaco de Puma Biotech
